Bibliography
- Smith HW , ButterfieldA, SunD. Detection of antibodies against therapeutic proteins in the presence of residual therapeutic protein using a solid-phase extraction with acid dissociation (SPEAD) sample treatment prior to ELISA. Regulatory Toxicology and Pharmacology. 49(3), 230–237 (2007).
- Koren E , ZuckermanLA, Mire-SluisAR. Immune responses to therapeutic proteins in humans – clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3(11), 349–360 (2002).
- US Department of Health and Human Services, Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry Bioanalytical Method Validation, May 2001.
- DeSilva B , SmithW, WeinerRet al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885–1900 (2003).
Websites
- Therapeutic Immunogenicity Focus Group of the American Association of Pharmaceutical Scientists. www.aaps.org/inside/focus_groups/TherPro/index.asp (Accessed June2011).
- Global Bioanalysis Consortium. www.globalbioanalysisconsortium.org (Accessed June2011).